Multiple Sclerosis Drugs - Puerto Rico

Puerto Rico

The Multiple Sclerosis Drugs market in Puerto Rico is expected to witness significant growth in the coming years.
By 2024, the projected revenue is estimated to reach US$6.89m.
Furthermore, the market is expected to exhibit a steady annual growth rate of 0.77% between 2024 and 2029, resulting in a market volume of US$7.16m by 2029.
When compared globally, United States is anticipated to generate the highest revenue in the Multiple Sclerosis Drugs market.
In 2024, it is projected to generate a staggering US$11,770.00m.
In Puerto Rico, the demand for Multiple Sclerosis drugs is on the rise due to the increasing prevalence of the disease in the population.

Key regions: France, India, United Kingdom, South Korea, Japan

Market

Region

Region comparison

Currency

Analyst Opinion

The Multiple Sclerosis Drugs market in Puerto Rico has been experiencing a steady growth in recent years.

Customer preferences: Patients in Puerto Rico suffering from Multiple Sclerosis have been increasingly opting for oral medications over injectables due to convenience and ease of use. Additionally, there has been a growing preference for disease-modifying therapies that can slow down the progression of the disease.

Trends in the market: One of the major trends in the Multiple Sclerosis Drugs market in Puerto Rico is the increasing use of biosimilars. These drugs are becoming more popular due to their lower cost as compared to the branded drugs. Another trend is the use of combination therapies, where two or more drugs are used together to provide better disease control.

Local special circumstances: Puerto Rico has a high prevalence of Multiple Sclerosis, which has led to a greater demand for drugs that can effectively treat the disease. Additionally, the island has a large aging population, which is more susceptible to developing Multiple Sclerosis.

Underlying macroeconomic factors: Puerto Rico has been facing economic challenges in recent years, which has led to a decrease in healthcare spending. However, the government has been taking steps to increase access to healthcare, which has led to an increase in the demand for Multiple Sclerosis drugs. Additionally, the island has a strong pharmaceutical manufacturing industry, which has helped to boost the availability of drugs in the market.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.